P0000001	resistant###NONE###NONE [SEP] advanced###NONE###NONE [SEP] locally advanced###NONE###NONE [SEP] non-metastatic###NONE###NONE [SEP] metastatic###NONE###NONE [SEP] unresectable###NONE###NONE [SEP] relapsed###NONE###NONE [SEP] relapse###NONE###NONE [SEP] relapsing###NONE###NONE [SEP] refractory###NONE###NONE [SEP] advanced###NONE###NONE [SEP] localised###NONE###NONE [SEP] localized###NONE###NONE [SEP] measurable###NONE###NONE [SEP] advanced###NONE###NONE [SEP] advanced###NONE###NONE [SEP] recurrent###NONE###NONE [SEP] newly diagnosed###NONE###NONE [SEP] operable###NONE###NONE [SEP] inoperable###NONE###NONE [SEP] resectable###NONE###NONE [SEP] no distant metastatic###NONE###NONE [SEP] distant metastatic###NONE###NONE [SEP] high risk###NONE###NONE [SEP] low risk###NONE###NONE [SEP] intermediate risk###NONE###NONE [SEP] resected###NONE###NONE [SEP] poor risk###NONE###NONE [SEP] high grade###NONE###NONE [SEP] low grade###NONE###NONE [SEP] intermediate grade###NONE###NONE [SEP] extensive stage###NONE###NONE [SEP] any stage###NONE###NONE [SEP] advanced stage###NONE###NONE [SEP] early stage###NONE###NONE	P0000001	Pharmcube Disease Label	\N
P0000002	first line###NONE###NONE  [SEP] second line###NONE###NONE  [SEP] third line###NONE###NONE  [SEP] fourth line###NONE###NONE  [SEP] fifth line###NONE###NONE  [SEP] sixth line###NONE###NONE  [SEP] seventh line###NONE###NONE  [SEP] eighth line###NONE###NONE  [SEP] ninth line###NONE###NONE  [SEP] first line therapy###NONE###NONE  [SEP] second line therapy###NONE###NONE  [SEP] third line therapy###NONE###NONE  [SEP] fourth line therapy###NONE###NONE  [SEP] fifth line therapy###NONE###NONE  [SEP] sixth line therapy###NONE###NONE  [SEP] seventh line therapy###NONE###NONE  [SEP] eighth line therapy###NONE###NONE  [SEP] ninth line therapy###NONE###NONE  [SEP] first line treatment###NONE###NONE  [SEP] second line treatment###NONE###NONE  [SEP] third line treatment###NONE###NONE  [SEP] fourth line treatment###NONE###NONE  [SEP] fifth line treatment###NONE###NONE  [SEP] sixth line treatment###NONE###NONE  [SEP] seventh line treatment###NONE###NONE  [SEP] eighth line treatment###NONE###NONE  [SEP] ninth line treatment###NONE###NONE  [SEP] first line therapies###NONE###NONE  [SEP] second line therapies###NONE###NONE  [SEP] third line therapies###NONE###NONE  [SEP] fourth line therapies###NONE###NONE  [SEP] fifth line therapies###NONE###NONE  [SEP] sixth line therapies###NONE###NONE  [SEP] seventh line therapies###NONE###NONE  [SEP] eighth line therapies###NONE###NONE  [SEP] ninth line therapies###NONE###NONE  [SEP] relapsed###NONE###NONE [SEP] relapse###NONE###NONE [SEP] relapsing###NONE###NONE [SEP] refractory###NONE###NONE [SEP] neoadjuvant therapy###NONE###NONE [SEP] neoadjuvant###NONE###NONE [SEP] adjuvant therapy###NONE###NONE [SEP] adjuvant###NONE###NONE [SEP] adjuvant endocrine therapy###NONE###NONE [SEP] adjuvant endocrine###NONE###NONE [SEP] adjuvant initial therapy###NONE###NONE [SEP] adjuvant extended therapy###NONE###NONE [SEP] induction therapy###NONE###NONE [SEP] initial therapy###NONE###NONE [SEP] initial endocrine therapy###NONE###NONE [SEP] extended endocrine therapy###NONE###NONE [SEP] consolidation therapy###NONE###NONE [SEP] maintenance therapy###NONE###NONE [SEP] second-line and above therapy###NONE###NONE [SEP] follow-up therapy###NONE###NONE [SEP] other therapy###NONE###NONE [SEP] last-line therapy###NONE###NONE [SEP] palliative therapy###NONE###NONE [SEP] relapse therapy###NONE###NONE [SEP] salvage therapy###NONE###NONE [SEP] preventive therapy###NONE###NONE [SEP] neoadjuvant therapies###NONE###NONE [SEP] adjuvant therapies###NONE###NONE [SEP] adjuvant endocrine therapies###NONE###NONE [SEP] adjuvant initial therapies###NONE###NONE [SEP] adjuvant extended therapies###NONE###NONE [SEP] induction therapies###NONE###NONE [SEP] initial therapies###NONE###NONE [SEP] initial endocrine therapies###NONE###NONE [SEP] extended endocrine therapies###NONE###NONE [SEP] consolidation therapies###NONE###NONE [SEP] maintenance therapies###NONE###NONE [SEP] second-line and above therapies###NONE###NONE [SEP] follow-up therapies###NONE###NONE [SEP] other therapies###NONE###NONE [SEP] last-line therapies###NONE###NONE [SEP] palliative therapies###NONE###NONE [SEP] relapse therapies###NONE###NONE [SEP] salvage therapies###NONE###NONE [SEP] preventive therapies###NONE###NONE [SEP] neoadjuvant treatment###NONE###NONE [SEP] adjuvant treatment###NONE###NONE [SEP] adjuvant endocrine treatment###NONE###NONE [SEP] adjuvant initial treatment###NONE###NONE [SEP] adjuvant extended treatment###NONE###NONE [SEP] induction treatment###NONE###NONE [SEP] initial treatment###NONE###NONE [SEP] initial endocrine treatment###NONE###NONE [SEP] extended endocrine treatment###NONE###NONE [SEP] consolidation treatment###NONE###NONE [SEP] maintenance treatment###NONE###NONE [SEP] second-line and above treatment###NONE###NONE [SEP] follow-up treatment###NONE###NONE [SEP] other treatment###NONE###NONE [SEP] last-line treatment###NONE###NONE [SEP] palliative treatment###NONE###NONE [SEP] relapse treatment###NONE###NONE [SEP] salvage treatment###NONE###NONE [SEP] preventive treatment###NONE###NONE	P0000002	Pharmcube Therapy Label	\N
P0000003	≥18 years###NONE###NONE [SEP] young###NONE###NONE [SEP]  old###NONE###NONE [SEP]  adult###NONE###NONE [SEP]  adults###NONE###NONE [SEP]  childhood###NONE###NONE [SEP]  child###NONE###NONE [SEP]  children###NONE###NONE [SEP]  women###NONE###NONE [SEP]  untreated###NONE###NONE [SEP]  pretreated###NONE###NONE [SEP]  no prior therapy###NONE###NONE [SEP]  male###NONE###NONE [SEP]  female###NONE###NONE [SEP]  postmenopausal###NONE###NONE [SEP]  menopause###NONE###NONE [SEP]  treatment naive###NONE###NONE [SEP] united states###NONE###NONE [SEP]  american###NONE###NONE [SEP]  north american###NONE###NONE [SEP] south american###NONE###NONE [SEP] china###NONE###NONE [SEP]  chinese###NONE###NONE [SEP]  japan###NONE###NONE [SEP]  japanese###NONE###NONE [SEP]  germany###NONE###NONE [SEP]  german###NONE###NONE [SEP]  united kingdom###NONE###NONE [SEP]  british###NONE###NONE [SEP]  india###NONE###NONE [SEP]  indian###NONE###NONE [SEP]  france###NONE###NONE [SEP]  french###NONE###NONE [SEP]  italy###NONE###NONE [SEP]  italian###NONE###NONE [SEP]  canada###NONE###NONE [SEP]  canadian###NONE###NONE [SEP]  korea###NONE###NONE [SEP]  korean###NONE###NONE [SEP]  brazil###NONE###NONE [SEP]  brazilian###NONE###NONE [SEP]  australia###NONE###NONE [SEP]  australian###NONE###NONE [SEP]  mexico###NONE###NONE [SEP]  mexican###NONE###NONE [SEP]  asian###NONE###NONE [SEP]  european###NONE###NONE [SEP]  african###NONE###NONE [SEP] newly diagnosed###NONE###NONE	P0000003	Pharmcube Patient Label	\N
P0000004	EGFR (S492R)###NONE###NONE [SEP] ERBB2 oncogenic mutation###NONE###NONE [SEP] KIT (627-664,664-714,449-514)###NONE###NONE [SEP] ABL1 (T315I)###NONE###NONE [SEP] BRAF (Y472C)###NONE###NONE [SEP] BCL6 positive###NONE###NONE [SEP] SLC29A1 oncogenic mutation###NONE###NONE [SEP] KIT mutation in exon 11###NONE###NONE [SEP] AR amplification###NONE###NONE [SEP] CHEK2 deletion###NONE###NONE [SEP] KIT mutation in exon 17###NONE###NONE [SEP] HER2 positive (HR negative)###NONE###NONE [SEP] PD-L1 expression＜1%###NONE###NONE [SEP] FGFR2 fusion###NONE###NONE [SEP] PDGFRA (P577S,R841K,H845Y,G853D)###NONE###NONE [SEP] NRAS oncogenic mutation###NONE###NONE [SEP] KIT (D816V)###NONE###NONE [SEP] IGF-1R expression###NONE###NONE [SEP] NTRK3 fusion###NONE###NONE [SEP] FLT1 overexpression###NONE###NONE [SEP] NTRK1 (G595R,G667C)###NONE###NONE [SEP] BRCA2 germline mutation###NONE###NONE [SEP] MDM2 amplification###NONE###NONE [SEP] ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)###NONE###NONE [SEP] FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A)###NONE###NONE [SEP] ERBB2 expression###NONE###NONE [SEP] HDAC expression###NONE###NONE [SEP] KIT mutation in exon 9 or 11###NONE###NONE [SEP] KRAS oncogenic mutation###NONE###NONE [SEP] FGFR3-TACC3 fusion###NONE###NONE [SEP] AR-V7 positive###NONE###NONE [SEP] MPL (W515F)###NONE###NONE [SEP] MAP2K1 (P124)###NONE###NONE [SEP] IGF-1 expression###NONE###NONE [SEP] KRAS mutation###NONE###NONE [SEP] AKT1 (Q79K,E17K)###NONE###NONE [SEP] NTRK1 fusion###NONE###NONE [SEP] TBX21 overexpression###NONE###NONE [SEP] PIK3CB oncogenic mutation###NONE###NONE [SEP] BCOR oncogenic mutation###NONE###NONE [SEP] NOTCH1 oncogenic mutation###NONE###NONE [SEP] MYC overexpression###NONE###NONE [SEP] PIK expression###NONE###NONE [SEP] FLCN deletion###NONE###NONE [SEP] JAK3 (R657Q,I87T,Q501H)###NONE###NONE [SEP] LRP1B deletion###NONE###NONE [SEP] PIK3R2 (A171V,N561D)###NONE###NONE [SEP] PD-L1 expression1%-49%###NONE###NONE [SEP] TPMT biallelic inactivation###NONE###NONE [SEP] BRAF (K601R,L597R,V600R)###NONE###NONE [SEP] XPO1 positive###NONE###NONE [SEP] MCL1 amplification###NONE###NONE [SEP] ALK (G1123S)###NONE###NONE [SEP] MET mutation in exon 16-19###NONE###NONE [SEP] NF2 deletion###NONE###NONE [SEP] BRAF G466V mutation###NONE###NONE [SEP] RAF1 overexpression###NONE###NONE [SEP] ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)###NONE###NONE [SEP] MYC amplification###NONE###NONE [SEP] IGF-1R activation###NONE###NONE [SEP] CD274 overexpression###NONE###NONE [SEP] EGFR mutation###NONE###NONE [SEP] EGFR exon 20 insertion###NONE###NONE [SEP] TP53 wildtype###NONE###NONE [SEP] FGFR1 amplification###NONE###NONE [SEP] EGFR exon 19 deletion###NONE###NONE [SEP] ERCC2 oncogenic mutation###NONE###NONE [SEP] KIT (A829P,V654A,T670I)###NONE###NONE [SEP] FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)###NONE###NONE [SEP] PDL1 overexpression###NONE###NONE [SEP] AR overexpression###NONE###NONE [SEP] PIK3CB (D1067Y)###NONE###NONE [SEP] MET (H1112R)###NONE###NONE [SEP] FGFR1 amplification###NONE###NONE [SEP] ALK rearrangement###NONE###NONE [SEP] EGFR exon 19 deletion###NONE###NONE [SEP] PIK3C3 mutation###NONE###NONE [SEP] MET exon 14 skipping mutations###NONE###NONE [SEP] KIT (D816Y,D816F,D816V)###NONE###NONE [SEP] EGFR L858R/T790M mutation###NONE###NONE [SEP] BAP1 deletion###NONE###NONE [SEP] HGF amplification###NONE###NONE [SEP] ROS1 negative###NONE###NONE [SEP] SMARCA1 oncogenic mutation###NONE###NONE [SEP] CHD4 overexpression###NONE###NONE [SEP] DNMT3A oncogenic mutation###NONE###NONE [SEP] dMMR###NONE###NONE [SEP] PBRM1 oncogenic mutation###NONE###NONE [SEP] KIT mutation in exon 9 or 17###NONE###NONE [SEP] KIT (H697Y)###NONE###NONE [SEP] BCL2 amplification###NONE###NONE [SEP] EGFR overexpression###NONE###NONE [SEP] EGFR-A763_Y764insFQEA###NONE###NONE [SEP] DDR positive###NONE###NONE [SEP] FGFR3 overexpression###NONE###NONE [SEP] TPMT splice acceptor variant###NONE###NONE [SEP] BCL2 overexpression###NONE###NONE [SEP] SH2B3 deletion###NONE###NONE [SEP] FGFR2 inframe insertion (A266),inframe insertion (S267)###NONE###NONE [SEP] FGFR3 (S249C,G691R)###NONE###NONE [SEP] MTOR (F2108L)###NONE###NONE [SEP] disialoganglioside GD2 positive###NONE###NONE [SEP] MET (Y1230C;Y1235D)###NONE###NONE [SEP] ERBB2 overexpression###NONE###NONE [SEP] mTOR mutation###NONE###NONE [SEP] MET (V1110I,H1112R,M1268T,R988C,T1010I)###NONE###NONE [SEP] TMPRSS2 fusion###NONE###NONE [SEP] ALK (L1196M)###NONE###NONE [SEP] EGFR-RAD51 fusion###NONE###NONE [SEP] TP53 oncogenic mutation###NONE###NONE [SEP] KIT amplification###NONE###NONE [SEP] FAT1 oncogenic mutation###NONE###NONE [SEP] PDGFRA D842V mutation###NONE###NONE [SEP] ANXA1 overexpression###NONE###NONE [SEP] BRAF (V600R)###NONE###NONE [SEP] KIT (D820Y)###NONE###NONE [SEP] CD19 mutation###NONE###NONE [SEP] EGFR (A289V,R108K,G598V,T263P)###NONE###NONE [SEP] BCL2 positive###NONE###NONE [SEP] BRAF (V600D,V600K,V600M,V600G,V600R)###NONE###NONE [SEP] KRAS wild-type###NONE###NONE [SEP] BRAF (V600E,G469A)###NONE###NONE [SEP] SRSF2 oncogenic mutation###NONE###NONE [SEP] FGFR3 (Y373C)###NONE###NONE [SEP] ERBB3 (G284R,R103G)###NONE###NONE [SEP] EGFR exon 20 insertion###NONE###NONE [SEP] ALK mutation###NONE###NONE [SEP] PALB2 oncogenic mutation###NONE###NONE [SEP] CCNE1 amplification###NONE###NONE [SEP] RAD51C oncogenic mutation###NONE###NONE [SEP] tumor mutation burden###NONE###NONE [SEP] NKX2-1 amplification###NONE###NONE [SEP] GNA11 (Q209L,Q209P)###NONE###NONE [SEP] CSF3R frameshift variant (D771),frameshift variant (S783)###NONE###NONE [SEP] EML4-ALK fusion###NONE###NONE [SEP] dMMR deletion###NONE###NONE [SEP] LRP1B oncogenic mutation###NONE###NONE [SEP] HER2 overexpression###NONE###NONE [SEP] NF2 oncogenic mutation###NONE###NONE [SEP] KCNJ5 (L168R)###NONE###NONE [SEP] G6PD overexpression###NONE###NONE [SEP] CCND1 amplification###NONE###NONE [SEP] EGFR (V843I) mutation###NONE###NONE [SEP] CCND1 amplification###NONE###NONE [SEP] MTOR (I1973F)###NONE###NONE [SEP] CDK12 oncogenic mutation###NONE###NONE [SEP] NOTCH1 fusion###NONE###NONE [SEP] MAP2K1 (Q56P,P124S,P124L)###NONE###NONE [SEP] KRAS (G12)###NONE###NONE [SEP] PARP expression###NONE###NONE [SEP] MKI67 overexpression###NONE###NONE [SEP] EPHA2 (G391R)###NONE###NONE [SEP] NRAS (G12C)###NONE###NONE [SEP] MDM4 amplification###NONE###NONE [SEP] ERCC1 oncogenic mutation###NONE###NONE [SEP] AURKA amplification###NONE###NONE [SEP] TOP2A amplification###NONE###NONE [SEP] CRBN (Q100*,R283K)###NONE###NONE [SEP] PBRM1 deletion###NONE###NONE [SEP] ALK positive###NONE###NONE [SEP] AKT3 fusion###NONE###NONE [SEP] RET rearrangement###NONE###NONE [SEP] KRAS (G13D)###NONE###NONE [SEP] PDGFRA fusion###NONE###NONE [SEP] AR (L702H,T878A)###NONE###NONE [SEP] KIT (550-592,627-664,788-828,829-860)###NONE###NONE [SEP] IL7R inframe deletion (237-255)###NONE###NONE [SEP] IDH2 (R140K,R172K)###NONE###NONE [SEP] TSC1 deletion###NONE###NONE [SEP] BRAF oncogenic mutation###NONE###NONE [SEP] MAP2K1 F129L mutation###NONE###NONE [SEP] TP53 (R248Q,R175H)###NONE###NONE [SEP] BRCA1 germline mutation###NONE###NONE [SEP] ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)###NONE###NONE [SEP] CYP17A1 expression###NONE###NONE [SEP] CDK6 amplification###NONE###NONE [SEP] EGFR oncogenic mutation###NONE###NONE [SEP] PTPRD oncogenic mutation###NONE###NONE [SEP] PAX5 mutation###NONE###NONE [SEP] HER2D16 positive###NONE###NONE [SEP] hTERT overexpression###NONE###NONE [SEP] ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)###NONE###NONE [SEP] PD-L1 expression≥50%###NONE###NONE [SEP] MET (D1246V)###NONE###NONE [SEP] ERBB2 (T798I)###NONE###NONE [SEP] IDH1 oncogenic mutation###NONE###NONE [SEP] ERBB2 (G776L)###NONE###NONE [SEP] EGFR (S7681,L861Q,G719X)###NONE###NONE [SEP] CRLF2 fusion###NONE###NONE [SEP] EGFR (L718)###NONE###NONE [SEP] EGFR L858R/T790M mutation###NONE###NONE [SEP] ESR1 oncogenic mutation###NONE###NONE [SEP] STK11 deletion###NONE###NONE [SEP] BRAF (D594G,G469E)###NONE###NONE [SEP] EGFR (S464L,G465R,I491M)###NONE###NONE [SEP] Chr t(11;14)  mutation###NONE###NONE [SEP] BRCA2 oncogenic mutation###NONE###NONE [SEP] ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe\ninsertion (G776YVMA)###NONE###NONE [SEP] c-MET overexpression###NONE###NONE [SEP] IGF1R activation###NONE###NONE [SEP] SMARCB1 oncogenic mutation###NONE###NONE [SEP] AR expression###NONE###NONE [SEP] EGFR (D761Y)###NONE###NONE [SEP] FGFR expression###NONE###NONE [SEP] Chr del(13q)###NONE###NONE [SEP] HER2 negative###NONE###NONE [SEP] EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)###NONE###NONE [SEP] TSC2 deletion###NONE###NONE [SEP] RET (618,620,634,768,791,891,918,C634W,M918T)###NONE###NONE [SEP] FLT3 (D835,Y842)###NONE###NONE [SEP] SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)###NONE###NONE [SEP] AKT1 (H238Y)###NONE###NONE [SEP] TUBB3 overexpression###NONE###NONE [SEP] SERPINB3 oncogenic mutation###NONE###NONE [SEP] MAP2K1 (K57T)###NONE###NONE [SEP] SMO (P641A)###NONE###NONE [SEP] triple negative###NONE###NONE [SEP] BRCA1 oncogenic mutation###NONE###NONE [SEP] IGF1R amplification###NONE###NONE [SEP] high level MET amplification###NONE###NONE [SEP] PDGFRA (V658A,P577S,R841K,H845Y,G853D)###NONE###NONE [SEP] NRAS (Q61)###NONE###NONE [SEP] Luminal A###NONE###NONE [SEP] PD-L1 positive###NONE###NONE [SEP] FGFR4 (N535,V550)###NONE###NONE [SEP] PDGFRA (D842V)###NONE###NONE [SEP] HIF1A overexpression###NONE###NONE [SEP] PALB2 deletion###NONE###NONE [SEP] PLCG2 (R665W,L845F)###NONE###NONE [SEP] DPYD splice donor variant###NONE###NONE [SEP] del(17p)/TP53 mutation###NONE###NONE [SEP] MET (H1112L)###NONE###NONE [SEP] FRS2 amplification###NONE###NONE [SEP] RB1 expression###NONE###NONE [SEP] MAP2K1 (E203K,Q56P,K57E)###NONE###NONE [SEP] MAP2K1 oncogenic mutation###NONE###NONE [SEP] ALK oncogenic mutation###NONE###NONE [SEP] CA9 overexpression###NONE###NONE [SEP] BRD4-C15orf55 fusion###NONE###NONE [SEP] CCND1 expression###NONE###NONE [SEP] ALK (C1156Y)###NONE###NONE [SEP] KIT (788-828,829-860,550-592)###NONE###NONE [SEP] CBL (Y371H,C384R)###NONE###NONE [SEP] IRS1 activation###NONE###NONE [SEP] GNAQ G48V mutation###NONE###NONE [SEP] FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)###NONE###NONE [SEP] BRAF inframe deletion (L485),inframe deletion (P490)###NONE###NONE [SEP] MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)###NONE###NONE [SEP] ALK (I1171N)###NONE###NONE [SEP] AR (T878A)###NONE###NONE [SEP] JAK1 (S646F;R683)###NONE###NONE [SEP] KIT (N822K)###NONE###NONE [SEP] ALK (E1408V)###NONE###NONE [SEP] HYAL4-V1 expression###NONE###NONE [SEP] ESR1 overexpression###NONE###NONE [SEP] EGFR (L792)###NONE###NONE [SEP] EGFR (S720) mutation###NONE###NONE [SEP] without del(17p)/TP53 mutation###NONE###NONE [SEP] BTK expression###NONE###NONE [SEP] POLE (268-471)###NONE###NONE [SEP] IGF-2 expression###NONE###NONE [SEP] JAK2 oncogenic mutation###NONE###NONE [SEP] SF3B1 (K700E,K666N)###NONE###NONE [SEP] GNAQ (Q209)###NONE###NONE [SEP] FGF4 amplification###NONE###NONE [SEP] RB1 overexpression###NONE###NONE [SEP] c-KIT positive###NONE###NONE [SEP] CDK4 oncogenic mutation###NONE###NONE [SEP] BAP1 oncogenic mutation###NONE###NONE [SEP] KRAS G12C mutation###NONE###NONE [SEP] MAP2K2 (V35M,L46F,N126D,C125S)###NONE###NONE [SEP] CYSLTR2 L129Q mutation###NONE###NONE [SEP] PIK3CA mutation + HER2 positive###NONE###NONE [SEP] EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)###NONE###NONE [SEP] STK11 (D194E)###NONE###NONE [SEP] G6PD (V98M)###NONE###NONE [SEP] RB1 oncogenic mutation###NONE###NONE [SEP] CD69 undexpression###NONE###NONE [SEP] ERBB2 proximal exon 20###NONE###NONE [SEP] MLL fusion###NONE###NONE [SEP] MET exon14 alteration###NONE###NONE [SEP] ATR oncogenic mutation###NONE###NONE [SEP] SH2B3 oncogenic mutation###NONE###NONE [SEP] DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)###NONE###NONE [SEP] ERBB4 S774G mutation###NONE###NONE [SEP] PML-RARA fusion###NONE###NONE [SEP] FGFR3 oncogenic mutation###NONE###NONE [SEP] EGFRC797S/L798I mutation###NONE###NONE [SEP] MAP2K1 (P124L,K57N,C121S)###NONE###NONE [SEP] ERCC6 oncogenic mutation###NONE###NONE [SEP] HER2 positive###NONE###NONE [SEP] EGFR (L858R)###NONE###NONE [SEP] ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)###NONE###NONE [SEP] GATA3 oncogenic mutation###NONE###NONE [SEP] NF1 mutation###NONE###NONE [SEP] FGFR3 deletion###NONE###NONE [SEP] MGMT promoter methylation###NONE###NONE [SEP] CDKN1A oncogenic mutation###NONE###NONE [SEP] PDGFRA amplification###NONE###NONE [SEP] kRAS G12V mutation###NONE###NONE [SEP] EREG amplification###NONE###NONE [SEP] ROS1 fusion###NONE###NONE [SEP] CCND1 expression###NONE###NONE [SEP] MTOR (Q2223K)###NONE###NONE [SEP] AREG amplification###NONE###NONE [SEP] UGT1A1 (G71R,P229Q)###NONE###NONE [SEP] ARAF (S214C)###NONE###NONE [SEP] PBRM1 undexpression###NONE###NONE [SEP] EGFR-KDD positive###NONE###NONE [SEP] EGFR-C797S mutation###NONE###NONE [SEP] FGFR2 (W290C,S320C,K660N)###NONE###NONE [SEP] ARID1A oncogenic mutation###NONE###NONE [SEP] SETD2 oncogenic mutation###NONE###NONE [SEP] ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)###NONE###NONE [SEP] BRAF (V600E,V600K)###NONE###NONE [SEP] BCL-XL underexpression###NONE###NONE [SEP] PLK1 expression###NONE###NONE [SEP] AR positive###NONE###NONE [SEP] CD58 mutation###NONE###NONE [SEP] SMARCA4 deletion###NONE###NONE [SEP] PTEN oncogenic mutation###NONE###NONE [SEP] NFKBIA amplification###NONE###NONE [SEP] TPMT (A80P,Y240C,A154T,A167G)###NONE###NONE [SEP] SMARCB1 deletion###NONE###NONE [SEP] BRAF (V600)###NONE###NONE [SEP] CCND1 deletion###NONE###NONE [SEP] ERCC4 oncogenic mutation###NONE###NONE [SEP] GLI2 amplification###NONE###NONE [SEP] MAP2K1 (P124S,I111S)###NONE###NONE [SEP] IGF-1R activation###NONE###NONE [SEP] CDK12 amplification###NONE###NONE [SEP] AR negative###NONE###NONE [SEP] PSMA positive###NONE###NONE [SEP] ESR1-YAP1 fusion###NONE###NONE [SEP] MAP2K1 (Q56P)###NONE###NONE [SEP] HASPIN expression###NONE###NONE [SEP] ERBB2 (V659E)###NONE###NONE [SEP] TRK fusion###NONE###NONE [SEP] RET mutation###NONE###NONE [SEP] JAK3 (A572V,A573V)###NONE###NONE [SEP] CDK4 amplification###NONE###NONE [SEP] BRCA2 deletion###NONE###NONE [SEP] UGT1A1 biallelic inactivation###NONE###NONE [SEP] ERBB2 amplification###NONE###NONE [SEP] ALK (L1198F)###NONE###NONE [SEP] FANCC oncogenic mutation###NONE###NONE [SEP] APC oncogenic mutation###NONE###NONE [SEP] NPM1 oncogenic mutation###NONE###NONE [SEP] EGFR (L798I)###NONE###NONE [SEP] gBRCA1/2 mutation###NONE###NONE [SEP] ERBB4 fusion###NONE###NONE [SEP] PTEN deletion###NONE###NONE [SEP] MAP2K1 (F129L,L215P,I103N,P124)###NONE###NONE [SEP] TSC2 (Q1178*)###NONE###NONE [SEP] EGFR amplification###NONE###NONE [SEP] SMO (D473H)###NONE###NONE [SEP] CDH1 oncogenic mutation###NONE###NONE [SEP] MAP2K1 (Q56P,P124S,P124L;C121S)###NONE###NONE [SEP] VEGF positive###NONE###NONE [SEP] HGF overexpression###NONE###NONE [SEP] ERBB3 (P262H,G284R)###NONE###NONE [SEP] IGHV mutation###NONE###NONE [SEP] SETD2 deletion###NONE###NONE [SEP] B2M oncogenic mutation###NONE###NONE [SEP] SLC44A4 overexpression###NONE###NONE [SEP] HER2 amplification###NONE###NONE [SEP] VEGF expression###NONE###NONE [SEP] ROS1 (G2032R)###NONE###NONE [SEP] ERBB3 (P262H,G284R,Q809R)###NONE###NONE [SEP] PDGFRA inframe deletion (I843)###NONE###NONE [SEP] G6PD biallelic inactivation###NONE###NONE [SEP] AR (F877L)###NONE###NONE [SEP] CDCA3 overexpression###NONE###NONE [SEP] MAP2K1 (C121S)###NONE###NONE [SEP] CDKN2C deletion###NONE###NONE [SEP] FGFR2 amplification###NONE###NONE [SEP] EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)###NONE###NONE [SEP] G6PD (N156D)###NONE###NONE [SEP] PDGFRA (552-596,631-668,814-854)###NONE###NONE [SEP] EGFR (P546S)###NONE###NONE [SEP] RNF43 oncogenic mutation###NONE###NONE [SEP] ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)###NONE###NONE [SEP] CDKN2C oncogenic mutation###NONE###NONE [SEP] GATA3 mutation###NONE###NONE [SEP] HER2 mutation###NONE###NONE [SEP] MYC positive###NONE###NONE [SEP] EGFR exon 19 mutation###NONE###NONE [SEP] EGFR inframe insertion (769-770)###NONE###NONE [SEP] PAK1 amplification###NONE###NONE [SEP] ALK-TKI resistance mutations###NONE###NONE [SEP] FGFR2 (V565I)###NONE###NONE [SEP] SOCS1 mutation###NONE###NONE [SEP] ARID1A amplification###NONE###NONE [SEP] BRAF (V600E,V600D,V600K,V600M,V600G,V600R)###NONE###NONE [SEP] RAC1 (P29S) oncogenic mutation###NONE###NONE [SEP] FANCC deletion###NONE###NONE [SEP] GNAS (R201)###NONE###NONE [SEP] ALK inframe insertion (1151T)###NONE###NONE [SEP] NRG1 fusion###NONE###NONE [SEP] PRKCH amplification###NONE###NONE [SEP] ER positive###NONE###NONE [SEP] HER2 expression and RAS wildtype###NONE###NONE [SEP] ESR1 (Y537S)###NONE###NONE [SEP] ALK (C1156Y,L1196M)###NONE###NONE [SEP] BRCA1 deletion###NONE###NONE [SEP] PIK3CA mutation###NONE###NONE [SEP] NF1 biallelic inactivation###NONE###NONE [SEP] DPYD (I560S,D949V)###NONE###NONE [SEP] GRB2 expression###NONE###NONE [SEP] MITF amplification###NONE###NONE [SEP] ALK G1202R mutation###NONE###NONE [SEP] NTRK fusion###NONE###NONE [SEP] CDKN1A deletion###NONE###NONE [SEP] MLL2 oncogenic mutation###NONE###NONE [SEP] BTK (C481)###NONE###NONE [SEP] CDKN2B oncogenic mutation###NONE###NONE [SEP] RB1 deletion###NONE###NONE [SEP] ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)###NONE###NONE [SEP] EGFR inframe deletion (6-273)###NONE###NONE [SEP] JAK2 (V617F)###NONE###NONE [SEP] CDK4 amplification###NONE###NONE [SEP] FMS-liketyrosine kinease 3-internal tandem duplication###NONE###NONE [SEP] RET (I788N)###NONE###NONE [SEP] KIT mutation in exon 17 or 18###NONE###NONE [SEP] KIT exon 9 mutation###NONE###NONE [SEP] EGFR (E690K)###NONE###NONE [SEP] KIT (Y553N)###NONE###NONE [SEP] ATR deletion###NONE###NONE [SEP] mTOR L1433S mutation###NONE###NONE [SEP] FGF3 amplification###NONE###NONE [SEP] CDKN1B oncogenic mutation###NONE###NONE [SEP] FGFR3 mRNA overexpression###NONE###NONE [SEP] PI3K activation###NONE###NONE [SEP] CREBBP mutation###NONE###NONE [SEP] IDH1 (R132)###NONE###NONE [SEP] TSC2 oncogenic mutation###NONE###NONE [SEP] ERBB2 (K753E)###NONE###NONE [SEP] SUZ12 deletion###NONE###NONE [SEP] IGF-2 activation###NONE###NONE [SEP] NOTCH2 fusion###NONE###NONE [SEP] PTEN biallelic inactivation###NONE###NONE [SEP] ERBB2 (S310,L755,V777)###NONE###NONE [SEP] EGFR C797S mutation###NONE###NONE [SEP] FLCN oncogenic mutation###NONE###NONE [SEP] IDH1 mutation###NONE###NONE [SEP] EGFR exon 19 insertion###NONE###NONE [SEP] ALK (I1171T)###NONE###NONE [SEP] ERBB4 (H809G)###NONE###NONE [SEP] PIK3CA amplification###NONE###NONE [SEP] GnRH receptor positive###NONE###NONE [SEP] ERBB4 (E317K,E452K,R544W,R393W,E872K)###NONE###NONE [SEP] HRR mutation###NONE###NONE [SEP] NTRK3 (G623R)###NONE###NONE [SEP] MYCN amplification###NONE###NONE [SEP] ARAF oncogenic mutation###NONE###NONE [SEP] PTEN oncogenic mutation###NONE###NONE [SEP] CDKN2A oncogenic mutation###NONE###NONE [SEP] ATM biallelic inactivation###NONE###NONE [SEP] ALK fusion###NONE###NONE [SEP] ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)###NONE###NONE [SEP] CSF1R (Y571D)###NONE###NONE [SEP] BCL6 overexpression###NONE###NONE [SEP] RET fusion-positive###NONE###NONE [SEP] FGFR positive###NONE###NONE [SEP] CHEK2 oncogenic mutation###NONE###NONE [SEP] HER2 positive (HR positive)###NONE###NONE [SEP] AR (F877L) + AR (T878A)###NONE###NONE [SEP] NTRK1 (G595R)###NONE###NONE [SEP] EPHA2 amplification###NONE###NONE [SEP] HDAC2 biallelic inactivation###NONE###NONE [SEP] PDGFRA (T674I)###NONE###NONE [SEP] SETD2 mutation###NONE###NONE [SEP] POLE oncogenic mutation###NONE###NONE [SEP] MCM4 overexpression###NONE###NONE [SEP] BRAF (G466V)###NONE###NONE [SEP] FLT3 (F691,D835,N676,Y842)###NONE###NONE [SEP] BRAF V600E mutation###NONE###NONE [SEP] KIF5B-EGFR fusion###NONE###NONE [SEP] PDGFB-COL1A1 fusion###NONE###NONE [SEP] EGFR (P753S)###NONE###NONE [SEP] PDGFRA-FIP1L1 fusion###NONE###NONE [SEP] RET (C634W,M918T)###NONE###NONE [SEP] KIT wildtype###NONE###NONE [SEP] ROS1 (S1986Y,S1986F)###NONE###NONE [SEP] FLT3 (N676)###NONE###NONE [SEP] IRF8 underexpression###NONE###NONE [SEP] BRAF V600E mutation###NONE###NONE [SEP] ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)###NONE###NONE [SEP] PR positive###NONE###NONE [SEP] NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop\nlost (2245-2536),frameshift variant (2245-2536)###NONE###NONE [SEP] EGFR inframe insertion (P753PS)###NONE###NONE [SEP] RAD50 (L1237F)###NONE###NONE [SEP] FOXA1 amplification###NONE###NONE [SEP] KDR (A1065T)###NONE###NONE [SEP] CXCR4 expression###NONE###NONE [SEP] KIT inframe deletion (577-579)###NONE###NONE [SEP] ALK negative###NONE###NONE [SEP] FGFR3 (K650)###NONE###NONE [SEP] ALK (F1174L)###NONE###NONE [SEP] PDPK1 amplification###NONE###NONE [SEP] VEGFA amplification###NONE###NONE [SEP] EML4-ALK fusion###NONE###NONE [SEP] BRAF (L597R)###NONE###NONE [SEP] KIT inframe deletion (V560)###NONE###NONE [SEP] CRBN expression###NONE###NONE [SEP] U2AF1 oncogenic mutation###NONE###NONE [SEP] high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)###NONE###NONE [SEP] KRAS amplification###NONE###NONE [SEP] PTCH1 oncogenic mutation###NONE###NONE [SEP] PDGFRA overexpression###NONE###NONE [SEP] ZBTB16 undexpression###NONE###NONE [SEP] ERCC1 deletion###NONE###NONE [SEP] KIT (T670I)###NONE###NONE [SEP] EGFR T790M mutation###NONE###NONE [SEP] FBXW7 oncogenic mutation###NONE###NONE [SEP] KRAS (12,13)###NONE###NONE [SEP] MET fusion###NONE###NONE [SEP] BRCA mutation###NONE###NONE [SEP] RAF1 (S257P,G361A,P261P)###NONE###NONE [SEP] disialoganglioside GD2 positive###NONE###NONE [SEP] EGFR exon 21 L858R mutation###NONE###NONE [SEP] EPHA3 amplification###NONE###NONE [SEP] GNAQ R183Q mutation###NONE###NONE [SEP] low expression of MMP9###NONE###NONE [SEP] MTOR (L1460P,S2215Y,R2505P)###NONE###NONE [SEP] INPP4B deletion###NONE###NONE [SEP] EGFR (S492R,G465R,R451C,K467T)###NONE###NONE [SEP] FGFR2 (S252W,N550K)###NONE###NONE [SEP] ERCC1 overexpression###NONE###NONE [SEP] JAK activation###NONE###NONE [SEP] ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)###NONE###NONE [SEP] DPYD biallelic inactivation###NONE###NONE [SEP] EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)###NONE###NONE [SEP] PTPRD mutation###NONE###NONE [SEP] PD-L1 expression≥20%###NONE###NONE [SEP] ERBB2 (V659E,S310F)###NONE###NONE [SEP] MTOR (E2014K,E2419K,N1421D)###NONE###NONE [SEP] STAG2 oncogenic mutation###NONE###NONE [SEP] Chr del(11q)###NONE###NONE [SEP] SMARCA4 oncogenic mutation###NONE###NONE [SEP] CTNNB1 oncogenic mutation###NONE###NONE [SEP] CDKN2A deletion###NONE###NONE [SEP] IDH2 oncogenic mutation###NONE###NONE [SEP] CREBBP mutation###NONE###NONE [SEP] BTK (C481S)###NONE###NONE [SEP] NF1 (D1644A)###NONE###NONE [SEP] JAK2 amplification###NONE###NONE [SEP] MSH3 oncogenic mutation###NONE###NONE [SEP] GATA3 overexpression###NONE###NONE [SEP] JAK2-BRAF fusion###NONE###NONE [SEP] PIK3R1 mutation###NONE###NONE [SEP] CDK6 oncogenic mutation###NONE###NONE [SEP] DDR positive###NONE###NONE [SEP] PI3K3CA###NONE###NONE [SEP] NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)###NONE###NONE [SEP] FBXW7 deletion###NONE###NONE [SEP] ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)###NONE###NONE [SEP] BRAF fusion###NONE###NONE [SEP] ALK (L1196M,S1206Y,G1269A,I1171T)###NONE###NONE [SEP] Luminal B (HER2 negative)###NONE###NONE [SEP] EGFR inframe deletion (L747)###NONE###NONE [SEP] Mcl-1 overexpression###NONE###NONE [SEP] TSC2 (E66K)###NONE###NONE [SEP] ALK G1269A mutation###NONE###NONE [SEP] ABL1 (V299L)###NONE###NONE [SEP] ZNRF3 oncogenic mutation###NONE###NONE [SEP] MYD88 (L265P)###NONE###NONE [SEP] EGFR (L858R,L861,G719,S768I)###NONE###NONE [SEP] EZH2 mutation###NONE###NONE [SEP] NRAS (12,13,59,61,117,146)###NONE###NONE [SEP] PIK3CA (E545*)###NONE###NONE [SEP] NF1 oncogenic mutation###NONE###NONE [SEP] EGFR (K757R,E746G)###NONE###NONE [SEP] CTNNB1 (H36Y,S37C,S37Y,D32V)###NONE###NONE [SEP] MAP2K1 inframe deletion (56-60)###NONE###NONE [SEP] CCND2 amplification###NONE###NONE [SEP] FANCA deletion###NONE###NONE [SEP] IGF-1 activation###NONE###NONE [SEP] EP300 mutation###NONE###NONE [SEP] KIT (D820E)###NONE###NONE [SEP] CD274 amplification###NONE###NONE [SEP] ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)###NONE###NONE [SEP] KIT mutation in exon 9,11,13,14 or 17###NONE###NONE [SEP] ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)###NONE###NONE [SEP] AKT2 amplification###NONE###NONE [SEP] NOTCH1 activating mutation in Cterm-PEST domain###NONE###NONE [SEP] SYK amplification###NONE###NONE [SEP] FGFR3 (V555M)###NONE###NONE [SEP] FGFR3 fusion###NONE###NONE [SEP] TSC1 oncogenic mutation###NONE###NONE [SEP] BRAF (L485W)###NONE###NONE [SEP] KRAS (12,13,59,61,117,146)###NONE###NONE [SEP] CCND3 amplification###NONE###NONE [SEP] ERBB2 (L869R)###NONE###NONE [SEP] FGFR fusion###NONE###NONE [SEP] MTOR (N1421D)###NONE###NONE [SEP] PLEKHM2-ALK fusion###NONE###NONE [SEP] VHL oncogenic mutation###NONE###NONE [SEP] MET kinase domain mutation###NONE###NONE [SEP] MAP2K2 (Q60P)###NONE###NONE [SEP] RICTOR amplification###NONE###NONE [SEP] PTPRT mutation###NONE###NONE [SEP] TERT promoters core###NONE###NONE [SEP] ROS1 rearrangement###NONE###NONE [SEP] EGFR (G465R)###NONE###NONE [SEP] BRAF (G469A)###NONE###NONE [SEP] TP53 deletion###NONE###NONE [SEP] MET amplification###NONE###NONE [SEP] G6PD (S218F)###NONE###NONE [SEP] AKT1 (E17K)###NONE###NONE [SEP] ERBB3 amplification###NONE###NONE [SEP] ITGA2 overexpression###NONE###NONE [SEP] FGFR1-3 expression###NONE###NONE [SEP] CDKN2B deletion###NONE###NONE [SEP] PDGFRA wildtype###NONE###NONE [SEP] DDR2 (S768R)###NONE###NONE [SEP] BRCA1 deletion###NONE###NONE [SEP] CYP17A1 expression###NONE###NONE [SEP] ERBB3 (G284R,V104M,R103G)###NONE###NONE [SEP] PIK3R1 oncogenic mutation###NONE###NONE [SEP] CREBBP inactivation###NONE###NONE [SEP] ALK (F856S,A348D)###NONE###NONE [SEP] BTK expression###NONE###NONE [SEP] CRBN oncogenic mutation###NONE###NONE [SEP] EGFR (T790M) mutation###NONE###NONE [SEP] MTOR (K1771R)###NONE###NONE [SEP] RAF1 fusion###NONE###NONE [SEP] ITGA2 overexpression###NONE###NONE [SEP] CDKN1B deletion###NONE###NONE [SEP] MET (M1268T)###NONE###NONE [SEP] FLT3 (D835)###NONE###NONE [SEP] KIT (D816)###NONE###NONE [SEP] EGFR inframe deletion (30-336)###NONE###NONE [SEP] HRAS oncogenic mutation###NONE###NONE [SEP] STK11 oncogenic mutation###NONE###NONE [SEP] IGF2 amplification###NONE###NONE [SEP] ATM deletion###NONE###NONE [SEP] GNAQ Q209L mutation###NONE###NONE [SEP] EGFR (C797S)###NONE###NONE [SEP] FANCA oncogenic mutation###NONE###NONE [SEP] RET-TPCN1 fusion###NONE###NONE [SEP] CREBBP inactivation###NONE###NONE [SEP] ABL1-BCR fusion###NONE###NONE [SEP] JAK1 oncogenic mutation###NONE###NONE [SEP] PD-L1 expression≥1%###NONE###NONE [SEP] KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)###NONE###NONE [SEP] SUZ12 oncogenic mutation###NONE###NONE [SEP] FLT3 mutation###NONE###NONE [SEP] NF1 deletion###NONE###NONE [SEP] IL7R inframe insertion (237-255)###NONE###NONE [SEP] progesterone receptor (PR) positive###NONE###NONE [SEP] TP53 mutation###NONE###NONE [SEP] ALK amplification###NONE###NONE [SEP] FLT3 (F691)###NONE###NONE [SEP] IL7R (S185C)###NONE###NONE [SEP] INPP4B oncogenic mutation###NONE###NONE [SEP] CRBN undexpression###NONE###NONE [SEP] MYC amplification###NONE###NONE [SEP] FGFR3 (K650,Y373C)###NONE###NONE [SEP] ERBB2/4 mutation###NONE###NONE [SEP] ESR1 (E380Q,537,538,L536,P535H)###NONE###NONE [SEP] IRF8 mutation###NONE###NONE [SEP] IDH2 (R172)###NONE###NONE [SEP] ATM oncogenic mutation###NONE###NONE [SEP] EZH2 (Y641,A677)###NONE###NONE [SEP] KIT inframe deletion (416-422),inframe insertion (416-422)###NONE###NONE [SEP] KIF5B-EGFR fusion###NONE###NONE	P0000004	Pharmcube Biomarker Label	\N